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ABSTRACT 
Blood brain barrier, poor solubility and low bioavailability (<27%) due to hepatic metabolism are major constraints of clozapine (CZP) oral 
tablets for their clinical application in the treatment of psychosis. Therefore, the study aims to develop pluronic based thermosensitive 
mucoadhesive in situ gel of clozapine for brain targeting through intranasal olfactory pathway. The objective of the present study was to develop 
an aqueous and oil based thermosensitive mucoadhesive in situ gel of clozapine for intranasal delivery and to evaluate the gels for in vitro 
characterization and ex vivo permeation in comparison to drug solution. The aqueous and oil based in situ gel systems were developed by cold 
method using water and oleic acid as solvents respectively. Combination of Pluronic F-127 and F-68 (20:2) were used as thermosensitive gelling 
agents.  Labrasol and Transcutol P at 1:1 ratio were employed as co solvents for the solubilisation of drug. The prepared in situ gels were 
evaluated for clarity, gelation temperature (Tsol-gel), gelation time (GT), gel strength (GS), pH, viscosity, mucoadhesive strength and ex vivo drug 
permeation studies. The effect of mucoadhesive agents like Chitosan, Sodium-β- glycerophosphate and Polyox WSR303 on gelation temperature 
(Tsol-gel) and drug permeation was also evaluated. The optimized aqueous in situ gel with 0.5% chitosan (Fa15) showed viscosity 
554.66±8.73cP at 31oC; mucoadhesive strength 5114.91±107.37dynes/cm2, gelation temperature (Tsol-gel) 29.6±1.7 oC and gelation time (GT) 
69±5 sec. The flux was found to be 243.46 µg/cm2/hr which was significantly high (p<0.0001) compared to drug solution and the enhancement 
ratio(ER) was found to be 2.28 folds to the drug solution whereas the oil gel showed flux of 190.34 µg/cm2/hr and enhancement ratio was found 
to be1.64 folds to the drug solution. The results indicated that the hydrogels are potential carriers than oil gels for delivery of clozapine via 
intranasal route. 
Keywords: Clozapine, in situ gels, nasal drug delivery, olfactory pathway, brain targeting, psychosis 
 
 Article Info: Received 19 Feb 2019;   Review Completed 26 March 2019;   Accepted 28 March 2019;   Available online 15 April 2019 
Cite this article as: 
Ravikrishna V, Krishnaveni J, Development and evaluation of clozapine intranasal mucoadhesive in situ gels 
for brain targeting, Journal of Drug Delivery and Therapeutics. 2019; 9(2-s):198-207    
http://dx.doi.org/10.22270/jddt.v9i2-s.2491         
*Address for Correspondence:  
Dr. J. Krishnaveni, Assistant Professor, Department of Pharmaceutics, UCPSc, Kakatiya University, Warangal,       
Telangana, India 
 
1. INTRODUCTION 
The mental and behavioural disorders are chronic, severe 
and disabling brain disorders affecting people throughout 
life. In India, it is estimated that 6-7% population suffer from 
common mental disorders and 1-2% severe mental 
disorders. The economic burden of schizophrenia is 
particularly great; approximately, the treatment consumes a 
total of $ 63 billion per year 1, 2.  
Clozapine (CZP) is a prototype atypical antipsychotic drug 
used to treat patients with schizophrenia who are 
unresponsive or intolerant to typical antipsychotics. 
Clozapine acts through a combination of antagonistic effects 
at D2 receptors in the mesolimbic pathway and 5-HT2A 
receptors in the frontal cortex. D2 antagonism relieves 
positive symptoms while 5-HT2A antagonism alleviates 
negative symptoms. Clozapine is also more effective in 
resistant schizophrenia and reduces suicidal behavior in 
patients which is common with the case of older 
antipsychotics 30, 31. 
The clozapine absorbed from oral tablets reach brain to 
small extent due to blood brain barrier and degradation in GI 
harsh environment and extensive hepatic first pass 
metabolism and hence poor bioavailability (<27) due to 
extensive first pass effect by CYP1A2 and CYP3A4. Many 
patients (69-82%) discontinue medication due to its 
intolerable side effects. Hence, it is worth exploring 
alternative routes of administration to avoid its first-pass 
metabolism as well as to enhance the bioavailability and 
brain targeting efficiency of CZP 3.    
 In recent times, interest in intranasal route to target drugs 
to brain circumventing blood–brain barrier has gained 
importance 4. This method works because of the unique 
connection between the nose and the brain through olfactory 
nerve pathway 5. Intranasal drug administration has been 
considered to treat neuropsychiatric disorder due to the 
advantages brought by the highly vascularised nasal 
epithelium, which gives extraordinary permeability of drugs 
and therefore results in rapid drug absorption 6. This 
approach can also avoid the first pass metabolism and 
provides a practical, non-invasive, rapid and efficient method 
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to deliver drug molecules to the brain 5. Many of the 
researchers have proved and reported that various nasal 
formulations including microemulsions, nanoparticulates, 
microspheres and thermoreversible in situ gels can be 
employed to transport the drug molecules effectively to 
central nervous system (CNS) via olfactory and trigeminal 
neural pathways. However, the major problems that persist 
with nasal solutions are cleared off rapidly from nasal cavity 
due to mucociliary clearance. Therefore, designing an 
intranasal dosage form with mucoadhesive character is 
particularly helpful as it provides intimate contact between 
dosage form and nasal epithelium and increased residence 
time thereby maximizing the chances of absorption for a 
drug molecule 4, 7. The in situ gelling polymers are suitable 
approaches to enhance the nasal bioavailability aim by 
prolonging the contact time with the nasal surface 8. 
An in situ gel system (‘In-situ’ is a Latin word which means ‘in 
position’) is a drug delivery system that exhibits sol- to –gel 
phase transition due to change in specific physicochemical 
parameters such as ionic strength, temperature or pH. The 
principal advantage of in situ gels is that they can be easily 
instilled in liquid form and are capable of prolonging the 
residence time of the formulation on the surface of the nasal 
cavity due to gelling nature at nasal temperature 7, 8. 
The most commonly used thermoreversible in situ gels are 
those prepared from diblock polymers poly (ethylene oxide)-
b-poly (propylene oxide)-b-poly (ethylene oxide) popularly 
known as: Pluronics, Tetronics, Poloxamers etc. Pluronic F 
127 is widely used as a thermosensitive gelling agent since it 
is non-toxic, non-irritating, poses good release 
characteristics, has poor inherent mucoadhesive properties. 
Therefore, mucoadhesive polymer such as chitosan was 
added along with poloxamers to make effective intranasal in 
situ gel formulation 4, 9, 10. 
Therefore, in the present research work, intranasal 
thermoreversible mucoadhesive in situ gels of clozapine 
were developed using pluronic. The main objective behind 
this study is to increase the residence time of drug in nasal 
cavity by minimizing the anterior leakage of formulation and 
post-nasal drip, thereby maximizing the absorption of drug 
and its bioavailability to brain via olfactory pathway. 
2. MATERIALS AND METHODS 
 2.1. Materials 
Clozapine was a kind gift from Aurobindo Pharmaceuticals 
Ltd (Hyderabad, India); Pluronics (PF-127, PF-68) were 
purchased from BASF Chemical Ltd (Chennai, India); 
Labrasol and Transcutol-P were gifted from Gattefosse Pvt. 
Ltd. (Mumbai, India); Chitosan (CH; low molecular weight) 
was purchased from Sigma-Aldrich (Bangalore, India); Oleic 
acid was purchased from SD fine chemicals Ltd (Mumbai 
,India); Sodium-β-glycerophosphate was purchased from 
Sisco research lab Pvt Ltd,(Tabja, India); Polyox WSR-303 
was purchased from Dow chemical Pvt Ltd (Mumbai, India) 
All other reagents were of analytical grade. Water 
purification system (Millipore, MA, USA) was used to obtain 
high quality water. 
2.2. Preformulation studies 
2.2.1. Construction of standard graph of Clozapine 
(CZP) 
The standard graph of clozapine was constructed in different 
solvents such as methanol, water, phosphate buffer saline pH 
6.4, phosphate buffers of pH 5.5, 6.8 and 7.4 by using UV-
visible spectrophotometer (Labindia, 3000+). 
50 mg of the Clozapine was weighed accurately and 
transferred into the 50 mL volumetric flask. The drug was 
dissolved in sufficient quantity of solvent and volume was 
made up to the mark to get a 1 mg/mL (Stock-A). Stock-A 
was further diluted to obtain desired concentrations. The 
absorbance of samples was measured at 216 nm against 
blank. A standard graph was plotted by taking concentration 
(µg) on X-axis and absorbance (nm) on Y-axis 11. 
2.2.2. Differential scanning colorimetry  
Differential Scanning Colorimetry (DSC) of pure drug 
(Clozapine) was determined by using DSC instrument 
(Shimadzu, DSC W70). About 10 mg of CZP was weighed and 
sealed in standard DSC aluminum pans, crimped it and then 
scanned over a temperature range from 50 oC to 200 oC at a 
heating rate 10 oC/min. The empty aluminium pan was used 
as reference cell 12. 
2.2.3. Solubility studies 
An excess amount of drug was taken into vials containing 
5mL of solvents. Vials were closed and constantly agitated at 
37± 2oC for 48 hrs by using thermo regulatory water bath 
shaker (Remi Instruments, Mumbai). The sample was 
filtered through 0.2µm syringe filter and the amount of drug 
solubilized was estimated by UV method described earlier 13. 
2.3. Preparation and optimization of nasal in situ Gels 
2.3.1. Preparation of thermosensitive gel 
The thermosensitive gel was prepared using cold method 14, 
15. The  required amount of pluronic (PF-127) was slowly 
added into the required amount of cold purified water with 
continuous stirring for 15 min, and then the dispersion was 
kept overnight at 2-8˚C until a transparent hydrogel was 
obtained. Then, the required amount of drug and 
mucoadhesive agent dissolved in co solvent mixture was 
added to preformed gel with continuous stirring. The final 
weight of preparation was adjusted with water in case of 
aqueous gels and with oleic acid in case of oily gels. The 
dispersion was stored in refrigerator overnight to obtain a 
clear and transparent gel.  The composition of CZP in situ 
formulations was given in Table 1a (aqueous gels) & 1b (oil 
gels)
Table 1a: Composition of clozapine nasal mucoadhesive in situ gels (aqueous based) 
Ingredients 
(%w/w) 
Formulations 
Fa0 Fa1 Fa2 Fa3 Fa4 Fa5 Fa6 Fa7 Fa8 Fa9 Fa10 Fa11 Fa12 Fa13 Fa14 Fa15 
CZP   5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
PF-127 - 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 
PF-68             - 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
PWSR303 - 0.1 0.2 0.3 0.4 0.5 - - - - - - - - - - 
Sod.β-GP    - - - - - - 0.1 0.2 0.3 0.4 0.5 - - - - - 
Chitosan - - - - - - - - - - - 0.1 0.2 0.3 0.4 0.5 
L:Tp (1:1)       25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 
Water q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         
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Table 1b: Composition of clozapine nasal mucoadhesive in situ gels (oil based) 
Ingredients 
(%w/w) 
Formulations 
Fo0 Fo1 Fo2 Fo3 Fo4 Fo5 Fo6 Fo7 Fo8 Fo9 Fo10 Fo11 Fo12 Fo13 Fo14 Fo15 
CZP   5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
PF-127 - 20 20 20 20 20 20 20 20 20 20 20 20 20 20 20 
PF-68             - 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
PWSR303 - 0.1 0.2 0.3 0.4 0.5 - - - - - - - - - - 
Sod.β-GP    - - - - - - 0.1 0.2 0.3 0.4 0.5 - - - - - 
Chitosan - - - - - - - - - - - 0.1 0.2 0.3 0.4 0.5 
L:Tp (1:1)       25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 
Oleic Acid q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         q.s         
CZP-Clozapine; PF-Pluronic F; PWSR-Polyox WSR; Sod.β-GP-Sodium β glycerophosphate L: Tp-Labrasol: Transcutol P; Fa- aqueous based gel 
formulations; Fo-oil based gel formulations 
2.3.2.  Screening and optimization of PF-127& PF-68 
Concentrations for gelation 
 The preliminary screening was carried out using different 
proportions of Pluronic-F127 (10-22% w/w) and Pluronic F-
68(2-8%w/w) as shown in Table 2.  The gels were prepared 
as described in section.2.3.1. The gelation temperature was 
determined at each combination as per the method 
described in 2.4.1. The proportion of PF-127/PF-68 which 
showed gelation temperature (Tsol-gel) of 31-32°C was 
selected for further development of clozapine formulation 16. 
2.3.3. Preparation of Clozapine Solution (CZP-Plain) 
The Clozapine solution was prepared by dissolving clozapine 
(5%w/w) in weighed amount of Labrasol and Transcutol-P 
(1:1)(25%w/w) and made the final weight  with water for 
aqueous solution and with oleic acid for oily solution. The pH 
of the solution was adjusted to 5.5±0.2 using 0.1M HCl 17. 
2.4. Physicochemical characterization of prepared in 
situ gels 
 2.4.1. Determination of Gelation temperature (Tsol-gel) 
and Gelation time (GT) 
The gelation temperature of formulation was determined by 
tube inversion method 18. The prepared formulation (~1g) 
was transferred to a test tube and the gelling temperature 
was measured by immersing it in a thermo regulatory water 
bath. The temperature was increased from 25∘C to 37∘C 
gradually with an increment of 1oC until gelation. The 
temperature was equilibrated for 5 min at each point and the 
test tube was removed and inverted immediately to observe 
the flow of the solution. The temperature at which the 
movement of the meniscus on tilting of tube was arrested 
was recorded as gelation temperature and the time in 
seconds was recorded as gelation time. 
2.4.2. Clarity 
 The clarity of the formulations before and after gelling was 
determined by visual examination against black and white 
background 19. 
2.4.3. pH 
The pH of prepared formulations was determined at 25±2 oC 
by using calibrated digital pH meter (LI120 pH meter, ELICO 
Ltd). The sufficient quantity of prepared formulation was 
taken in a 50 ml beaker and the glass electrode was 
sufficiently dipped into the formulations 4, 13. 
  2.4.4. Gel strength  
Gel strength was determined at gel state by graduated 
measuring jar and weight method 8. The 50 g of gel was 
placed in a 100mL graduated measuring cylinder.  The 
weight equivalent to 35 g applied to the gel and the time 
taken by the weight to sink 5 cm down through the gel was 
noted. The gel strength was measured as the time (seconds, 
generally 25-50 sec) required to move the weight 5 cm 
down. 
2.4.5. Drug content 
The in situ gel formulation equivalent to 10mg of clozapine 
was taken and suitably diluted with appropriate solvent.  
The drug content was estimated by UV method as described 
earlier 20.  
2.4.6. Rheological properties at solution and gel states  
The rheological properties of formulations at 25oC and 31oC 
were measured by using Brookfield DV-II + PRO viscometer 
with spindle no. 3 at 100 rpm.  The prepared formulation 
was taken in a beaker and the viscosity was measured by 
immersing the spindle 21, 22. 
2.4.7. Isolation of porcine nasal mucosa 
The porcine nose was obtained from local slaughter house 
immediately after its sacrifice. It was transported to 
laboratory by keeping it in the phosphate buffer saline (pH 
6.4). The intact nasal mucosa was separated from septum 
and the connective tissue using forceps and scissors without 
damaging the nasal mucosa and used within 30 min 22.  
2.4.8. Mucoadhesive strength 
Mucoadhesive strength of gel state formulation was 
determined using modified physical balance 4, 8, 21. The 
porcine nasal mucosa was used as biological membrane. Two 
cylindrical glass vials with 2.2 cm diameter and modified 
balance instrument were taken.  The left side pan of the 
balance was removed and vial was fixed at base of it with 
cyanoacrylate glue and the other vial was attached to left 
arm of balance. The nasal mucosa was tied to one side of the 
both vials.  The mucosa was hydrated with 100  L of 
phosphate buffer saline pH 6.4. The gel formulation 
equivalent to 10mg of CZP was placed on lower vial prior to 
testing. Then, the vials were held together for 2 min for their 
attachment.  After 2 min, weights were added to the right 
pan gradually until the mucosa was detached from each 
other. The total weight in grams required for the complete 
detachment of the mucosa was noted and the mucoadhesive 
strength in dyne/cm2 was determined by using the following 
formula. 
Mucoadhesive Strength (dynes/cm2) = m x g/A 
Where m is weight required for detachment in grams, g is 
acceleration due to gravity (980 cm/s2) and A is surface area 
of mucosa exposed (3.8 cm2) 
 
Ravikrishna et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):198-207 
ISSN: 2250-1177                                                                                  [201]                                                                                 CODEN (USA): JDDTAO 
2.4.9. Ex vivo permeation of selected CZP formulations 
Ex vivo drug permeation was studied as per the method 
described by Anuja Naik et al, 2014 22. This study was carried 
out for selected gels and plain drug solution using Franz 
diffusion cell and porcine nasal mucosa.  The freshly excised 
nasal mucosa was mounted on the Franz diffusion cell and 
clamped between the donor and receptor compartments and 
allowed to equilibrate for 30 min. The entire set up was 
placed on thermoregulatory magnetic stirrer and the 
temperature of the chamber was maintained at 31±0.5oC and 
stirred at 250±2 rpm. The formulation equivalent to 10 mg of 
CZP was placed in the donor compartment. The receiver 
compartment was filled with PBS pH 6.4. Samples (2mL) 
were withdrawn at the time intervals of 5, 15, 30, 60, 120, 
240, 360 and 480 min. After each withdrawal, equal volume 
of fresh PBS pH 6.4 was replaced in the receptor 
compartment. The samples were filtered through 0.2µm 
membrane filter, diluted and the absorbance was measured 
at 216 nm by using UV-Visible spectrophotometer. The 
cumulative amount of drug permeated at each time point 
was calculated by using following formula.  
 n-1 
Q = [CnV+∑CiS] 
Where, Q= Cumulative amount of drug permeated; Cn= 
Concentration of drug (μg/ml) in nth sample interval; V= 
Volume of Franz diffusion cell,  
n-1 
ΣCiS = Sum of drug concentration of sample (1to n-1)     
i =1         multiplied with sampling volume (S) 
 
2.4.10. Stability study 
Stability study was carried out for optimized formulation 
(Fa15) at 25 oC±2 and at 4 oC±2 for 3 months 8. Samples were 
withdrawn every month and analyzed for parameters like 
appearance, gelation temperature, viscosity, drug content, 
pH, ex vivo permeation of drug. After 3 months, the values of 
each observation were compared with the initial parameters. 
3. RESULTS AND DISCUSSION 
3.1. DSC thermogram of Clozapine 
 The DSC thermogram of clozapine showed a sharp 
endothermic peak at 186.35°C which corresponds to the 
melting point of clozapine which indicates crystalline and 
purity of drug. The thermogram was shown in Fig 1.
              i=1 
 
Figure 1:  DSC thermogram of clozapine (CZP) pure drug 
3.2. Solubility studies 
The solubility of clozapine in various solvents was found to 
be in the range of 0.014±0.001 to 155.54±2.72 mg/ml (Fig 
2). Based on CZP solubility, Transcutol P, Labrasol and Oleic 
acid were selected for development of CZP formulations.  
 
Figure 2: Solubility of clozapine in different solvents 
PB: Phosphate buffer; PBS-Phosphate buffer saline; IPA-Isopropyl 
alcohol; PEG-Polyethylene glycol 
 
3.3. Screening and optimization of composition 
The optimization of pluronic concentration to achieve 
desired gelation temperature (Tsol-gel) is a critical 
parameter during in situ gel development. Since the average 
temperature in human nose was reported to be 31oC. The 
nasal formulation should be converted to gel at nasal 
temperature (i.e. 31-32oC) (Shuai Qian et al 2014, previously 
Jacky, 198023; Proctor et al, 197724). Therefore, the 
preliminary attempts were made to optimize the most 
suitable concentration of PF-127 to form a gel at a 
temperature about 32 oC.  At 20% concentration of PF-
127showed gelation temperature 31.7±0.5 oC and hence 
selected for the formulation.  PF-127 concentration showed 
inverse relation to the gelation temperature (Fig 3). The 
similar effect was reported by Preeti Pandey et al, 2017 and 
Shuai Qian et al, 2014.  The gelation temperature increased 
as the PF-68 concentration increased (Fig 4). The 
formulation containing PF-127: PF-68 at 20:2 ratio showed 
optimal gelation temperature of 31.7±0.5 oC.  
Due to poor solubility of CZP, the required drug loading is 
not possible into a formulation (Yuan Yuan et al, 2012) 25.  
This problem was solved by solubilising drug in Labrasol and 
Transcutol P mixture (1:1). The co solvent mixture Labrasol: 
Transcutol P (1:1) proportion was studied between 10-25% 
at fixed pluronic combination (Table 3).  Increasing the 
concentration of surfactant, the gelation temperature also 
0 20 40 60 80 100 120 140 160 
Water 
Oleic acid 
Soyabean oil 
Sunflower oil 
Labrasol 
Tween 80 
Transcutol P 
PEG 400 
IPA 
PB pH 5.5 
PBS pH 6.4 
PB pH 6.8 
PB pH 7.4 
solubility (mg/ml) 
CZP Solubility 
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increased which could be due to disruption of gel network by surfactant molecules (Tsutomu Furuya et al, 2003) 26.  
 
Table 2: Gelation temperature and time of PF-127& PF-68 at different combinations 
PF-68 
(%w/w) 
PF-127 (%w/w) 
10 15 18 20 22 
Tsol-gel 
(oC) 
GT 
(sec) 
Tsol-gel 
 (oC) 
GT 
(sec) 
Tsol-gel 
 (oC) 
GT 
(sec) 
Tsol-gel 
 (oC) 
GT 
(sec) 
0 No gelation 
36.4±0.45 61±2 29.43±0.86 60±5 26.43±0.85 55±3 
2 No gelation 
37.63±0.41 70±5 31.7±0.55 65±5 27.16±0.35 58±2 
4 No gelation 
40.13±1.87 95±5 34.9±1.47 78±6 28.8±0.90 65±5 
6 No gelation 
41.40±1.01 105±10 37.73±0.68 85±5 35.8±1.30 70±5 
8 No gelation 
43.73±1.36 130±10 40.5±0.70 115±5 37.6±1.05 80±5 
Tsol-gel-Gelation temperature from sol-gel; GT-Gelation time; sec-seconds; oC-degree Celsius; Each value represents the mean ± 
SD (n=3); 
Table 3: Effect of co solvent mixture on Tsol-gel of PF-127&PF-68(20:2) 
      L:Tp (%w/w) Tsol-gel (oC) 
 0  31.7±0.55  
10  28.86±0.20  
15  29.9±0.74  
20  30.8±0.57  
25  31.66±0.59  
L: Tp: Labrasol: Transcutol P (1:1); Each value represents mean±SD (n=3) 
 
 
               Figure 3: Effect of Pluronic F-127 on Tsol-gel 
 
Figure 4: Effect of PF-68 on Tsol-gel at 20 % PF-127
3.4. Gelation Temperature (Tsol-gel) and Gelation time 
(GT) of prepared gels 
The Tsol-gel of aqueous based gel formulations was in the 
range of 27.03±0.41 to 31.93±0.8 oC and oil based gel 
formulations was 26.86±0.4 to 30.53±0.66 oC (Table 4a & 
4b). The effect of mucoadhesive agents such as Polyox WSR-
303 a water soluble resin, Sodium-β-Glycerophosphate and 1 
% w/w Chitosan (cationic polymer) was studied between the 
concentrations of 0.1% -0.5% w/w. The mucoadhesive 
polymers showed a concentration dependent Tsol–gel 
lowering effect (Fig 5a and Fig 5b).  This could be due to the 
mucoadhesive agent bind to polyethylene oxide (PEO) chains 
present in the poloxamer molecules promoting dehydration 
and causing an increase in entanglement of adjacent 
molecules with more extensive intermolecular hydrogen 
bonding (Yingting Wang et al, 2017; Yuan Yuan et al, 2012; 
Zaki et al., 200727). The most pronounced decreasing effect 
was observed with Polyox WSR 303 as it produced high 
viscous formulation. The aqueous gel (Fa3, Fa10 and Fa15) 
and oil gel (Fo1, Fo9 and Fo13) formulations which 
exhibiting of gelation within 29–30oC were selected for 
further studies. All the formulations were transparent and 
the gelation occurred within 3min. 
 
 
 
36.4 
29.43 
26.46 
24.6 
15 
20 
25 
30 
35 
40 
16 18 20 22 24 26 
T
so
l-
g
el
 (
o
C
) 
Conc. of Pluronic F-127 (% w/w) 
Conc. of PF-127 vs Tsol-gel  
PF127  
29.43 
31.7 
34.9 
37.73 
40.5 
28 
30 
32 
34 
36 
38 
40 
42 
0 2 4 6 8 10 
T
so
l-
g
el
 (
o
C
) 
Conc.of Pluronic F-68 (% w/w) 
Conc. of PF-68 vs Tsol-gel of PF-127 
PF 68 
Ravikrishna et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):198-207 
ISSN: 2250-1177                                                                                  [203]                                                                                 CODEN (USA): JDDTAO 
Table 4 a: Gelation temperature, Gelation time and % drug content of aqueous CZP nasal in situ gels 
F. code Tsol-gel (oC) GT (sec) % Drug content 
Fa0 _ _  99.97±0.01  
Fa1 31.66±1.48 90±1  99.53±0.49  
Fa2 30.36±0.90 82±2  98.67±1.07  
Fa3 29.43±0.47 78±2  99.84±0.12  
Fa4 27.9±0.50 70±1  99.53±0.47  
Fa5 27.03±0.41 65±1  99.62±0.32  
Fa6 31.93±0.80 126±2  99.46±0.62  
Fa7 31.03±1.09 102±10  98.74±0.85  
Fa8 30.66±0.51 90±5  99.15±0.64  
Fa9 30.26±0.45 81±6  99.42±0.45  
Fa10 29.86±0.65 95±5  99.75±0.20  
Fa11 31.83±0.51 102±7  99.9±0.06  
Fa12 30.46±0.35 94±4  99.92±0.03  
Fa13 30.23±0.45 84±2  99.72±0.16  
Fa14 30.00±1.94 73±2  99.44±0.68  
Fa15 29.6±1.70 69±5  99.95±0.02  
Fa-Aqueous based formulation; Tsol-gel-Gelation temperature for sol-gel; GT-Gelation time 
Note: All the formulations are yellowish, transparent &free flowing at 25oC and gelation at about 32oC 
 
Table 4 b: Gelation temp, Gelation time and % drug content of oily CZP nasal in situ gels 
F. code Tsol-gel (oC) GT (sec) % Drug content 
Fo0 _ _  99.9±0.07  
Fo1 29.1±0.36 85±7  99.35±0.52  
Fo2 28.36±1 78±2  98.67±0.99  
Fo3 28.10±0.30 72±2  99.42±0.49  
Fo4 27.86±0.4 68±1  98.99±0.96  
Fo5 26.86±0.4 62±2  99.44±0.45  
Fo6 30.53±0.66 92±3  99.29±0.63  
Fo7 30.30±0.45 87±5  99.56±0.52  
Fo8 30.10±0.36 80±10  98.76±0.81  
Fo9 29.33±0.89 75±3  99.61±0.56  
Fo10 28.30±0.52 71±2  98.69±1.14  
Fo11 30.36±0.81 74±2  99.44±0.59  
Fo12 30.16±0.65 70±2  99.75±0.17  
Fo13 29.23±0.55 68±2  99.87±0.07  
Fo14 28.2±1.35 66±4  99.6±0.55  
Fo15 27.56±0.65 64±2  99.5±0.73  
Fo-oil based formulations; Each value represents the mean ± SD (n=3); 
Note: All the formulations are yellowish, transparent & viscous flowing at 25oC and gelation at about 31oC 
 
 
Figure 5a: Effect of mucoadhesive agent on Tsol-gel 
(Aqueous based gels) 
 
Figure 5b: Effect of mucoadhesive agent on Tsol-gel (oil 
based gels) 
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3.5. pH of formulations 
The pH of the nasal formulation is important to avoid the 
irritation in the nasal cavity and it must be compatible with 
nasal secretions. In the present study, the pH of all 
formulation was adjusted to 5.5±0.2 with 0.1M HCl. 
3.6.  Drug content 
The drug content of all the gel formulations, drug solutions 
were found in the range of 98.67±0.99–99.97±0.01% and 
shown in tables 4a & 4b. 
3.7. Gel strength 
Gel strength was determined for selected formulations of 
aqueous and oil gels and results were shown in Table 5. It 
has been observed that gel strength was increased with the 
increase in the concentration of mucoadhesive polymer in 
the formulation. The oil based gel formulations showed 
higher gel strength than aqueous. The reason could be 
attributed to the oleic acid present in these formulations, as 
it has a tendency to increase the viscosity of the formulation. 
The gel strength values of both aqueous and oil formulations 
were between 35±5 sec and 75±5 sec. The formulations 
containing Polyox WSR 303 showed higher gel strength 75±5 
sec (in oil gel) and 67±7 sec (in aqueous gel) than chitosan 
and sodium-β-glycerophosphate 
Table 5: Tsol-gel, Gel strength and mucoadhesive strength of selected aqueous & oil gels 
F. code Tsol-gel (oC) GS (sec) MS (dynes/cm2) 
Aqueous Gels 
Fa0 _ _ _ 
Fa3 29.43±0.47 67±7 6060.52±128.94 
Fa10 29.86±0.65 35±5 4169.29±74.44 
Fa15 29.60±1.70 45±5 5114.91±107.37 
        Oil Gels    
Fo0 _ _ _ 
Fo1 29.10±0.36 75±5 7307.01±196.97 
Fo9 29.33±0.89 60±5 5054.73±92.98 
                   Fo13            29.23±0.55 70±5   6301.22±132.34 
Fa0-CZP plain solution (aqueous); Fa3-0.3% PWSR303; Fa10-0.5% Sod.β-GP; Fa15-0.5% Chitosan; Fo0-CZP plain solution (oil); Fo1-0.1% 
PWSR303; Fo9-0.4% Sod.β-GP; Fo13-0.3% Chitosan; GS-Gel Strength; MS-Mucoadhesive Strength;  Each value represents the mean ± SD (n=3) 
3.8. Rheological properties of selected formulations (at 
solution state and gel state) 
The viscosity of formulations was determined in solution 
state and gel state. The comparative profile between aqueous 
and an oil gels were shown in Fig 6. The higher viscosity 
values were obtained at 31oC and all formulations exhibited 
about 2 folds higher viscosity which indicated gelation of 
polymers at this temperature. The viscosity was 
proportional to the concentration of the mucoadhesive 
polymer in the formulation. The higher viscosity was 
produced by the formulations containing Polyox WSR303, 
followed by chitosan and sodium- β-glycerophosphate. The 
oil based gels showed extremely higher viscosities (~2 folds) 
than aqueous based gels. All the formulations had 
considerable flow at room temperature (25oC) whereas the 
flow was ceased at 31oC.  
 
Figure 6: Viscosity profile of selected in situ gels 
3.9. Mucoadhesive strength 
The mucoadhesive strength is an important parameter for 
nasal formulations since it increases residence time in nasal 
cavity and prolonging the drug release (Hitendra S. Mahajan 
et al, 2011). However excessive mucoadhesive strength can 
damage the mucous membrane, thus an optimal strength is 
required for a nasal formulation (Preeti Pandey et al, 2017; 
Boddupalli et al, 201028). The mucoadhesive strength 
between 4000-6000 dynes/cm2 was considered adequate for 
a nasal formulation (Yingting Wang et al, 2017). The highest 
mucoadhesive strength was found with Polyox WSR 303 
than chitosan and sodium-β-glycerophosphate in both types 
of gels. This is due to the fact that the formulations 
containing Polyox WSR 303 have high viscosity and chain 
flexibility which favours interaction with mucin.  The lowest 
mucoadhesive strength was produced by sodium-β-
glycerophosphate, whereas chitosan produced considerable 
mucoadhesion (5114.91±107.37dynes/cm2) in aqueous gels.  
The mucoadhesion of chitosan is due to the electrostatic 
attraction between the positively charged D-glucosamine 
units of chitosan and the negatively charged sialic acid and 
sulphate residues of mucin in nasal mucosa. The aqueous 
gels showed less mucoadhesive strength than oil gels due to 
the dilution effect of water and relatively weak cross-linked 
gel structure in aqueous gels. The decreasing order of 
mucoadhesive strength was observed as Polyox WSR 
303>Chitosan>Sodium-β-GP. The comparative profile of 
mucoadhesive strength between aqueous and an oil gels was 
shown in Fig 7. 
 
Figure 7: Mucoadhesive strength of selected in situ gels 
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3.10. Ex vivo permeation of selected CZP formulations 
The ex vivo permeation studies carried out for selected 
formulations and the profiles of aqueous and oily gels were 
shown in Fig 8a and Fig 8b. The flux and permeability 
coefficients were calculated and compared with drug 
solution (Table 6). From the ex vivo permeation profiles, the 
permeation of drug was not only affected by pluronic 
concentration but also by the type of mucoadhesive agent 
used.  All the formulations showed higher flux values when 
compared to drug solution. This could be due to the presence 
of Pluronic and cosolvents (L: Tp) which might also acts as 
permeation enhancers (Hitendra S. Mahajan et al, 2011; 
Parag M. Ved et al, 201129). The formulations composed of 
Polyox WSR 303 showed less flux values when compared to 
chitosan and sodium-β-GP due to. 
The flux values of oil based gels (136.47-190.34 µg/cm2/h) 
were less than the aqueous based gels (159.89-243.46 
µg/cm2/h) due to their high viscosity and strong 
mucoadhesiveness. The high mucoadhesiveness can also 
retard the drug permeation (Yuan Yuan et al, 2012). The 
highest flux and permeability coefficients were obtained 
with formulations composed of chitosan when compared to 
others. This could be due to an interaction of a positively 
charged amino group on the C-2 position of chitosan with 
negatively charged sites on the cell membranes and tight 
junctions of the mucosal epithelial cells to allow opening of 
the tight junctions (Shagupfta khan et al, 2010). The increase 
in permeation shows contribution of paracellular transport 
through tight junctions. Therefore, the formulation Fa15, an 
aqueous based in situ gel composed of 0.5% chitosan 
showed highest flux (243.46 µg/cm2/h) which was 
significantly high (p<0.0001) and 2.28 folds permeability 
enhancement than CZP plain drug solution. This greater 
permeability indicated that the entrapment of CZP in a 
hydrogel increases its diffusion. 
 
Table 6: Flux, permeability coefficient and enhancement ratios of selected in situ gels 
F.code 
Flux 
(µg/cm2/hr) 
Kp x 10-3 
(cm/hr) ER 
Aqueous Gels 
Fa0 106.34 10.63 1 
Fa3 159.89 15.98 1.50 
Fa10 167.26 16.72 1.57 
Fa15 243.46 24.34 2.28 
        Oil Gels    
Fo0 115.55 11.55 1 
Fo1 136.47 13.64 1.18 
Fo9 146.83 14.68 1.27 
                   Fo13                 190.34 19.03 1.64 
Kp- Permeability coefficient; ER-Enhancement ratio 
 
 
Figure 8a: Ex vivo permeation profile of CZP solution vs             Figure 8b: Ex vivo permeation profile of CZP solution vs 
selected Aqueous in situ gels                                                                      selected oil in situ gels 
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3.11. Stability studies for optimized (Fa15) formulation  
The stability studies carried out for optimized aqueous based in situ gel formulation (Fa15) for 3 months. The formulation was 
found to be stable with no remarkable change in appearance, gelation properties, viscosity, mucoadhesiveness, drug content, pH 
and ex vivo drug permeation profiles (Table 7). 
Table 7: Stability studies for optimized formulation (Fa15) 
Time 
period 
Drug 
content 
(%) 
Tsol-gel 
(oC) 
Viscosity(cP) MS 
(dynes/cm2) 
Cum.amt.drug 
Permeated 
(µg) 
Flux 
(µg/cm2/h) 
Kp ER 
at 25 oC at 31 oC 
Initial 99.95±0.02 29.6±1.7 290.66±5.13 554.66±8.73 5114.91±107.37 9253.91+269.44 243.46 24.34 2.28 
1 
month          
25oC 99.92±0.02 29.5±0.1 291±8.18 555±13.22 5123.50±82.90 9224.40±371.48 243.26 24.32 2.28 
4oC 99.93±0.04 29.5±0.2 290±6.24 557±15.71 5132.1±92.98 9166.53±342.14 218.36 21.83 2.05 
2 
month          
25oC 99.91±0.02 29.4±0.1 292±6.55 558.33±10.40 5157.89±51.57 9116.82±332.97 242.24 24.22 2.27 
4oC 99.90±0.01 29.4±0.2 293.33±7.63 559±11.53 5140.70±53.68 9056.18±329.72 218.36 21.83 2.05 
3 
month          
25oC 99.89±0.01 29.2±0.3 294.66±6.42 560.33±9.5 5175.08±64.90 9045.11±336.92 241.22 24.12 2.26 
4oC 99.90±0.01 29.3±0.2 294.33±5.03 560.66±14.01 5166.49±39.39 9000.64±329.72 217.95 21.79 2.04 
Each value represents the mean ± SD (n=3) 
Note: The appearance, pH of the formulation, Gelation time, Gelation strength were not changed significantly at entire period (not shown in 
table) 
 
CONCLUSIONS 
The intranasal mucoadhesive aqueous and oil based in situ 
gels of clozapine were developed successfully by cold 
method using Pluronic F127 and F68 as thermosensitive 
gelling agents and Labrasol, Transcutol P as co solvents. The 
aqueous based in situ gels of CZP were superior than the oil 
based in situ gels which showed higher flux and 
enhancement ratio of 2.28. It can be concluded that the 
aqueous and oil based in situ gel formulation containing 
0.5% chitosan  showed significantly high permeation in ex 
vivo studies compared to others. 
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